TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15727575
Drug: Endoscopic sinus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endoscopic sinus surgery and intranasal budesonide for 12 months
Study: 7595708
Drug: Vinorelbine (NVB)
DrugBank: Vinorelbine (DB00361)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vinorelbine (NVB) 30 mg/m2 weekly
Study: 7595708
Drug: Melphalan (ALK)
Normalized name: Melphalan
DrugBank: Melphalan (DB01042)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Melphalan (ALK) 25 mg/m2 every 4 weeks
Study: 2245951
Drug: morphine‐scopolamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: morphine‐scopolamine
Study: 28857719
Drug: Lisdexamfetamine dimesylate
Normalized name: Lisdexamfetamine Dimesylate
DrugBank: Lisdexamfetamine (DB01255)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Lisdexamfetamine dimesylate 10 mg
Study: 28857719
Drug: Lisdexamfetamine dimesylate
Normalized name: Lisdexamfetamine Dimesylate
DrugBank: Lisdexamfetamine (DB01255)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Lisdexamfetamine dimesylate 30 mg
Study: 25180798
Drug: Lisdexamfetamine dimesylate
Normalized name: Lisdexamfetamine Dimesylate
DrugBank: Lisdexamfetamine (DB01255)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Lisdexamfetamine dimesylate 50 mg
Study: 25180798
Drug: Lisdexamfetamine dimesylate
Normalized name: Lisdexamfetamine Dimesylate
DrugBank: Lisdexamfetamine (DB01255)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Lisdexamfetamine dimesylate 70 mg
Study: 28857719
Drug: Lisdexamfetamine dimesylate
Normalized name: Lisdexamfetamine Dimesylate
DrugBank: Lisdexamfetamine (DB01255)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Lisdexamfetamine dimesylate (all doses combined)
Study: 23610455
Drug: Chemotherapy treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy treatment with radiotherapy
Study: 21305536
Drug: High-dose omeprazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose omeprazole (80-mg bolus followed by 8-mg/h infusion for 72 hours)
Study: 21305536
Drug: Standard-dose omeprazole
Normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standard-dose omeprazole (40-mg intravenous infusion once daily for 3 days)
Study: 21305536
Drug: High-dose omeprazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose omeprazole
Study: 21305536
Drug: Standard-dose omeprazole
Normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standard-dose omeprazole
Study: 11793037
Drug: IL-2 receptor
Normalized name: Il-2 receptor alpha chain
Approvals — FDA: no, EMA: no, PMDA: no
Description: IL-2 receptor antagonists (basiliximab and daclizumab)
Study: 9408981
Drug: Group 1:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 1: single daily dose of netilmicin based upon weight, age and renal function (mean dose 298 +/- 29 mg, median 300 mg, range 250-350 mg)
Study: 9408981
Drug: Group 2:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 2: 150% of standard dose (mean 418 +/- 45 mg, median 400 mg, range 350-500 mg)
Study: 9408981
Drug: Group 3:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 3: 200% of standard dose (mean 525 +/- 41 mg, median 500 mg, range 400-550 mg)
Study: 9408981
Drug: Group 4:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 4: 250% of standard dose (mean 710 +/- 39 mg, median 650 mg, range 600-750 mg)
Study: 8254242
Drug: Carotid endarterectomy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carotid endarterectomy added to best medical care including aspirin and control of manageable risk factors
Study: 8254242
Drug: Best medical
Normalized name: calcium polycarbophil
DrugBank: Calcium polycarbophil (DB14684)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Best medical care including aspirin and control of manageable risk factors
Study: 29354950
Drug: Acupuncture combined
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture combined with medication (once a day, five times per week, for 6 weeks, total 30 times)
Study: 29354950
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (maintained original treatment with antihypertensive medication)
Study: 25257148
Drug: Extended-release quetiapine
Normalized name: quetiapine Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended-release quetiapine (quetiapine XR; 150 or 300 mg/day)
Study: 23713578
Drug: Intensive treatment
Normalized name: Head & Shoulders Intensive Treatment
DrugBank: Selenium Sulfide (DB00971)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive treatment to lower blood pressure (target systolic level <140 mm Hg within 1 hour)
Study: 23713578
Drug: Guideline-recommended treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guideline-recommended treatment (target systolic level <180 mm Hg)
Study: 23713578
Drug: Intensive treatment
Normalized name: Head & Shoulders Intensive Treatment
DrugBank: Selenium Sulfide (DB00971)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive treatment to lower blood pressure
Study: 21665546
Drug: recombinant LH
Approvals — FDA: no, EMA: no, PMDA: no
Description: recombinant LH (rLH) administration
Study: 21665546
Drug: rLH administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: rLH administration
Study: 11172114
Drug: Uterine balloon
Normalized name: gentamicin
DrugBank: Gentamicin (DB00798)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Uterine balloon therapy
Study: 24735024
Drug: Dignity therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dignity therapy + standard palliative care (SPC)
Study: 18172188
Drug: Neoadjuvant androgen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant androgen deprivation therapy (ADT) with goserelin 3.6 mg every 4 weeks and flutamide 250 mg tid for 2 months before and concurrent with external-beam radiotherapy (EBRT)
Study: 18172188
Drug: Neoadjuvant androgen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant androgen deprivation therapy (ADT) with EBRT
Study: 15567450
Drug: Armagnac (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Armagnac (30 ml/day for 2 weeks)
Study: 15567450
Drug: Vodka (same
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vodka (same alcoholic strength, 30 ml/day for 2 weeks)
Study: 11706098
Drug: Citicoline (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citicoline (1000 mg PO twice a day for 6 weeks)
Study: 7961535
Drug: Fluoxetine (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine (up to 80 mg daily)
Study: 7961535
Drug: Fluoxetine (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine (various doses: 20, 40, and 60 mg)
Study: 7961535
Drug: Fluoxetine (in
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine (in responder extension)
Study: 7961535
Drug: Fluoxetine (open-label
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine (open-label extension)
Study: 28866091
Drug: Sodium intake
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium intake measured by 24-hour urine collections (mean intake 3,903 mg/day, standard deviation 1037 mg/day)
Study: 22412088
Drug: Brachial infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Brachial infusion of NO synthase inhibitor (N(G)-monomethyl-l-arginine [L-NMMA])
Study: 22412088
Drug: Brachial infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Brachial infusion of cytochrome P450 epoxygenase inhibitor (fluconazole)
Study: 22412088
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of L-NMMA and fluconazole
Study: 20079863
Drug: Deferasirox 20
Normalized name: Deferasirox
DrugBank: Deferasirox (DB01609)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Deferasirox 20 mg/kg/day orally for 6 months
Study: 11078227
Drug: Adenosine (140
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adenosine (140 microg/kg/min for 6 minutes) and Heparin (10,000 U bolus)
Study: 30883671
Drug: 0.125% ropivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.125% ropivacaine + 100 mcg of fentanyl
Study: 30883671
Drug: 0.125% levobupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.125% levobupivacaine + 100 mcg of fentanyl
Study: 24671538
Drug: d-cycloserine (DCS)
Normalized name: D-Cycloserine
DrugBank: Cycloserine (DB00260)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: d-cycloserine (DCS) 250 mg
Study: 17160498
Drug: DFDBA/PRP combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: DFDBA/PRP combination
Study: 15684017
Drug: Photodynamic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Photodynamic therapy (PDT) combined with interstitial chemotherapy (carmustine) after microsurgery
Study: 11991437
Drug: Alendronate 10
Normalized name: ALENDRONATE 10MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alendronate 10 mg/day for 2 years
Study: 9489270
Drug: Empirically Supported
Approvals — FDA: no, EMA: no, PMDA: no
Description: Empirically Supported Treatments (ESTs)
Study: 9489270
Drug: Manualized treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manualized treatment
Study: 7611583
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg morphine intraarticularly diluted in 10 ml saline
Study: 7611583
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg morphine intravenously diluted in 10 ml saline (control)
Study: 76170
Drug: Aluminium hydroxide
Normalized name: Aluminium hydroxide
DrugBank: Aluminum hydroxide (DB06723)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aluminium hydroxide in large doses
Study: 27736795
Drug: Standard regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard regimen of split-dose 4L polyethylene-glycol (group A)
Study: 27736795
Drug: Split-dose sodium
Normalized name: influenza A virus (H1N1) antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Split-dose sodium picosulphate/magnesium citrate (group B)
Study: 27736795
Drug: Individualized preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individualized preparation based on a 3-item questionnaire (group C)
Study: 27736795
Drug: Split-dose 4L
Normalized name: influenza A virus (H1N1) antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Split-dose 4L polyethylene-glycol
Study: 22232849
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg film-coated tablet (FCT)
Study: 22232849
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg chewable tablet (CT)
Study: 19188334
Drug: Midazolam (0.02‐0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam (0.02‐0.1 mg/kg per hour)
Study: 9314423
Drug: BNP infusion
Normalized name: BNP
DrugBank: Nesiritide (DB04899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: BNP infusion at a rate of 3.3 pmol x kg(‐1) x min(‐1) over 4 hours
Study: 31791663
Drug: Low-dose combination
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose combination intravitreal anti-PDGFRβ 1 mg and aflibercept 2 mg (LD combo)
Study: 31791663
Drug: High-dose combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose combination intravitreal anti-PDGFRβ 3 mg and aflibercept 2 mg (HD combo)
Study: 31791663
Drug: Intravitreal aflibercept
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal aflibercept injection (IAI) alone
Study: 26294293
Drug: Calcium (1200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium (1200 mg/day) and Vitamin D (800 IU/day)
Study: 26294293
Drug: Calcium (1200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium (1200 mg/day), Vitamin D (800 IU/day), and Strontium ranelate (2 g daily)
Study: 26200465
Drug: Physostigmine (0.24
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physostigmine (0.24 µg·kg·min)
Study: 24135387
Drug: Impaired fasting
Normalized name: Fast Freeze
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Impaired fasting glucose (IFG) defined as 100-125 mg/dL
Study: 21107327
Drug: losartan 50
Normalized name: LOSARTAN 50MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: losartan 50 mg per day, titrated to 100 mg per day for 13 months
Study: 21107327
Drug: ramipril 5
Normalized name: ramipril 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: ramipril 5 mg per day, titrated to 10 mg per day for 13 months
Study: 13677026
Drug: Fenspiride (Erespal)
Normalized name: fenspiride
DrugBank: Fenspiride (DB08979)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenspiride (Erespal) 80 mg per os 3 times a day for 10 days
Study: 1492852
Drug: Loxiglumide 400
Normalized name: Dexloxiglumide
DrugBank: Dexloxiglumide (DB04856)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loxiglumide 400 mg
Study: 1492852
Drug: Loxiglumide 800
Normalized name: Dexloxiglumide
DrugBank: Dexloxiglumide (DB04856)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loxiglumide 800 mg
Study: 30775944
Drug: Diuretic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diuretic therapy (DIUR-T)
Study: 19143907
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of sildenafil and doxazosin
Study: 17314057
Drug: recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: recombinant human growth hormone (rhGH) therapy, subcutaneous ingestion of 0.03-0.04 mg/kg once daily
Study: 15134414
Drug: Theraflex-TMJ cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Theraflex-TMJ cream
Study: 9613278
Drug: Ketamine 10
Normalized name: ketamine 10 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine 10 mg (1 ml)
Study: 3200265
Drug: Ursodeoxycholic acid
Normalized name: Ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ursodeoxycholic acid (1200 mg per day)
Study: 3200265
Drug: Aspirin (1300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (1300 mg per day)
Study: 23472197
Drug: CDP323 100
Normalized name: CDP323
DrugBank: CDP323 (DB05092)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CDP323 100 mg bid
Study: 23472197
Drug: CDP323 500
Normalized name: CDP323
DrugBank: CDP323 (DB05092)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CDP323 500 mg bid
Study: 23472197
Drug: CDP323 1000
Normalized name: CDP323
DrugBank: CDP323 (DB05092)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CDP323 1000 mg qd
Study: 23472197
Drug: CDP323 1000
Normalized name: CDP323
DrugBank: CDP323 (DB05092)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CDP323 1000 mg bid
Study: 14656749
Drug: Lipid administration
Normalized name: Lipid Administration Set 81"
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lipid administration in ARDS patients
Study: 14656749
Drug: Placebo administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administration in ARDS patients
Study: 14656749
Drug: Lipid administration
Normalized name: Lipid Administration Set 81"
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lipid administration in patients without ARDS
Study: 25897797
Drug: Prodromal Detection
Normalized name: alpha tocopherol / ascorbic acid / cholecalciferol / docosahexaenoic acid / docusate sodium / ferrous fumarate / folic acid / pyridoxine hydrochloride / tricalcium phosphate Oral Capsule [Nexa Select]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prodromal Detection and Treatment program (including information campaigns and detection teams)
Study: 20889164
Drug: Succimer chelation
Normalized name: Succimer
DrugBank: Succimer (DB00566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Succimer chelation treatment
Study: 18336963
Drug: Twinrix vaccine
Normalized name: TWINRIX vaccine 1 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twinrix vaccine administered according to a 0-, 1-, and 6-month schedule.
Study: 16464519
Drug: Atorvastatin (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin (40 mg for 10 days)
Study: 11737908
Drug: Short-term infusion
Normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Short-term infusion of corticosteroids
Study: 8477564
Drug: MS Contin
Normalized name: MS Contin
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: MS Contin tablets 90 mg
Study: 8477564
Drug: Oramorph SR
Normalized name: Oramorph SR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oramorph SR tablets 30 mg
Study: 8477564
Drug: Oramorph SR
Normalized name: Oramorph SR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oramorph SR tablets 90 mg
Study: 8477564
Drug: MS Contin
Normalized name: MS Contin
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: MS Contin tablets 30 mg
Study: 8477564
Drug: MS Contin
Normalized name: MS Contin
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: MS Contin tablets
Study: 8477564
Drug: Oramorph SR
Normalized name: Oramorph SR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oramorph SR tablets
Study: 21504886
Drug: Tobacco dependence
Normalized name: Tobacco leaf
DrugBank: Tobacco leaf (DB10710)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tobacco dependence treatment RCT incorporating behavioral counseling and nicotine replacement
Study: 17698902
Drug: Growth Hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth Hormone (GH) 4 IU subcutaneously every other day for 3 months
Study: 12536693
Drug: Buflomedil 100
Normalized name: buflomedil
DrugBank: Buflomedil (DB13510)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buflomedil 100 mg.d‐1
Study: 9270084
Drug: Systemic alpha1-receptor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic alpha1-receptor blockade (BLK)
Study: 3301710
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg femoxetine daily for 16 weeks
Study: 3301710
Drug: Placebo daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo daily for 16 weeks
Study: 3301710
Drug: Femoxetine in
Approvals — FDA: no, EMA: no, PMDA: no
Description: Femoxetine in subgroups of patients previously in anorectic treatment
Study: 31617649
Drug: Crocin (two
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crocin (two capsules per day for 28 days)
Study: 31617649
Drug: Placebo (two
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (two capsules per day for 28 days)
Study: 25629740
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg of subcutaneous icatibant
Study: 25629740
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy (intravenous prednisolone 500 mg plus clemastine 2 mg)
Study: 30139568
Drug: Phonophoresis with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phonophoresis with diclofenac + Thiocolchicoside gel (Group 1)
Study: 30139568
Drug: Ultrasound therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound therapy with non-therapeutic gel (Group 2)
Study: 20029243
Drug: Zaltoprofen 80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zaltoprofen 80 mg
Study: 18700222
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg intravenous diamorphine
Study: 18700222
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg subcutaneous hydromorphone
Study: 16251561
Drug: Halothane 2,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Halothane 2, 4, and 6 mL
Study: 16251561
Drug: Sevoflurane 5
Normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sevoflurane 5 mL
Study: 16251561
Drug: Halothane 1
Normalized name: halothane 1000 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Halothane 1 mL, Isoflurane 1.5 mL, Sevoflurane 2.7 mL
Study: 12717749
Drug: Test didanosine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test didanosine formulation (200 mg)
Study: 12717749
Drug: Reference didanosine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference didanosine formulation (200 mg)
Study: 1594257
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment group (n = 31)
Study: 25956588
Drug: Transdermal estradiol
Normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal estradiol (E2) 50 to 200 mcg/day
Study: 22233155
Drug: Nabilone (1,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nabilone (1, 2 or 3 mg)
Study: 18272031
Drug: Sunitinib as
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sunitinib as maintenance therapy
Study: 8355383
Drug: Prehospital-initiated treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prehospital-initiated treatment (aspirin and alteplase)
Study: 8355383
Drug: Hospital-initiated treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hospital-initiated treatment (aspirin and alteplase)
Study: 8355383
Drug: Treatment initiated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment initiated within 70 minutes of symptom onset (both prehospital and hospital)
Study: 3657877
Drug: Pneumococcus vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pneumococcus vaccine (control)
Study: 2477300
Drug: Contact endoscopic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Contact endoscopic laser treatment
Study: 2477300
Drug: Noncontact endoscopic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Noncontact endoscopic laser treatment
Study: 31354810
Drug: Calcium and
Normalized name: Calcium and Magnesium
DrugBank: Calcium carbonate (DB06724)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcium and vitamin D supplements
Study: 23574590
Drug: Drospirenone (DRSP)
Normalized name: Drospirenone
DrugBank: Drospirenone (DB01395)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Drospirenone (DRSP) with ethinyl-estradiol 20 μg (DRSP/EE20)
Study: 23574590
Drug: Drospirenone (DRSP)
Normalized name: Drospirenone
DrugBank: Drospirenone (DB01395)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Drospirenone (DRSP) with ethinyl-estradiol 30 μg (DRSP/EE30)
Study: 11385059
Drug: Vitamin E
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin E (250 IU d-alpha tocopherol 3 times daily for 1 year)
Study: 8338977
Drug: 1,25-(OH)2D 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1,25-(OH)2D 0.5 microgram/day + trichlormethiazide (TZ) 2 mg/day for 4 weeks
Study: 8338977
Drug: Long-term treatment
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term treatment with combined 1,25-(OH)2D and TZ for 11-29 months
Study: 17645559
Drug: Caiapo (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caiapo (4 g daily for 5 months)